The effect of oral methadone on the QTc interval in advanced cancer patients: A prospective pilot study

Journal of Palliative Medicine

Volumn 13, Issue 1, 2010, Pages 33-38

  Reddy, Suresh ^a   Hui, David ^a   Osta, Badi El ^a   De La Cruz, Maxine ^a   Walker, Paul ^a   Palmer, J Lynn ^a   Bruera, Eduardo ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PAIN; CANCER PATIENT; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG FATALITY; DRUG SAFETY; ELECTROCARDIOGRAPHY; ELECTROLYTE DISTURBANCE; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FLUTTER; HUMAN; MAJOR CLINICAL STUDY; MALE; PALLIATIVE THERAPY; PROSPECTIVE STUDY; QT INTERVAL; QT PROLONGATION;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; LONG QT SYNDROME; MALE; METHADONE; MIDDLE AGED; NEOPLASMS; PAIN; PILOT PROJECTS; PROSPECTIVE STUDIES;

EID: 74549168886     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2009.0184     Document Type: Article

References (42)

1. Bruera E, Sweeney C: Methadone use in cancer patients with pain: A review. J Palliat Med 2002;5:127-138.
2. Fredheim OM, Moksnes K, Borchgrevink PC, Kaasa S, Dale O: Clinical pharmacology of methadone for pain. Acta Anaesthesiol Scand 2008;52:879-889.
3. Mattick RP, Breen C, Kimber J, Davoli M: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2003; (2):CD002209.
4. Davis MP, Walsh D: Methadone for relief of cancer pain: A review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 2001;9:73-83.
5. Mannino R, Coyne P, Swainey C, Hansen LA, Lyckholm L: Methadone for cancer-related neuropathic pain: A review of the literature. J Opioid Manag 2006;2:269-276.
6. Nicholson AB: Methadone for cancer pain. Cochrane Database Syst Rev 2007;(4):CD003971.
7. Bruera E, Palmer JL, Bosnjak S, Rico MA, Moyano J, Sweeney C, Strasser F, Willey J, Bertolino M, Mathias C, Spruyt O, Fisch MJ: Methadone versus morphine as a first-line strong opioid for cancer pain: A randomized, double-blind study. J Clin Oncol 2004;22:185-192. (Pubitemid 41095131)
8. Lugo RA, Satterfield KL, Kern SE: Pharmacokinetics of methadone. J Pain Palliat Care Pharmacother 2005;19: 13-24.
9. Fainsinger RL, Louie K, Belzile M, Bruera E, Hanson J: Decreased opioid doses used on a palliative care unit. J Palliat Care 1996;12:6-9.
10. Kreek MJ, Schecter AJ, Gutjahr CL, Hecht M: Methadone use in patients with chronic renal disease. Drug Alcohol Depend 1980;5:197-205.
11. Cohen LM, Moss AH, Weisbord SD, Germain MJ: Renal palliative care. J Palliat Med 2006;9:977-992.
12. Benedetti C, Dickerson ED: Criteria for opioid selection. J Pain Symptom Manage 2000;19:410-411.
13. Elsayem A, Bruera E: Methadone-induced respiratory depression in a patient with a history of alcoholism. J Palliat Med 2005;8:1062-1066.
14. Benitez-Rosario MA, Salinas Martin A, Gomez-Ontanon E, Feria M: Methadone-induced respiratory depression after discontinuing carbamazepine administration. J Pain Symptom Manage 2006;32:99-100.
15. Lipski J, Stimmel B, Donoso E: The effect of heroin and multiple drug abuse on the electrocardiogram. Am Heart J 1973;86:663-668.
16. Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS: Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 2002;137:501-504.
17. Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohman RG: Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J 2007;153:891-899.
18. Pearson EC, Woosley RL: QT prolongation and torsades de pointes among methadone users: Reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf 2005;14:747-753.
19. Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS: Doserelated effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 2003; 23:802-805.
20. Peles E, Bodner G, KreekMJ, Rados V, AdelsonM: Corrected- QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: A cross-sectional study. Addiction 2007;102:289-300.
21. Walker PW, Klein D, Kasza L: High dose methadone and ventricular arrhythmias: A report of three cases. Pain 2003; 103:321-324.
22. Reddy S, Fisch M, Bruera E: Oral methadone for cancer pain: No indication of Q-T interval prolongation or torsades de pointes. J Pain Symptom Manage 2004;28:301-303.
23. Bazett HC: An analysis of the time-relations of electrocardograms. Heart 1920:353-370.
24. Available at: http://www.azcert.org/medical-pros/drug-lists/ bycategory.cfm#. (Last accessed April 2, 2009).
25. Roden DM: Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-1022.
26. Fredheim OM, Borchgrevink PC, Hegrenaes L, Kaasa S, Dale O, Klepstad P: Opioid switching from morphine to methadone causes a minor but not clinically significant increase in QTc time: A prospective 9-month follow-up study. J Pain Symptom Manage 2006;32:180-185.
27. Kornick CA, Kilborn MJ, Santiago-Palma J, Schulman G, Thaler HT, Keefe DL, Katchman AN, Pezzullo JC, Ebert SN, Woosley RL, Payne R, Manfredi PL: QTc interval prolongation associated with intravenous methadone. Pain 2003; 105:499-506.
28. Ferrer-Brechner T, Ganz P: Combination therapy with ibuprofen and methadone for chronic cancer pain. Am J Med 1984;77:78-83.
29. Ventafridda V, Ripamonti C, Bianchi M, Sbanotto A, De Conno F: A randomized study on oral administration of morphine and methadone in the treatment of cancer pain. J Pain Symptom Manage 1986;1:203-207.
30. Matts SG: Double blind trial of dextromoramide, methadone and pethidine in the treatment of severe pain. Postgrad Med J 1964;40:103-105.
31. Toombs JD, Kral LA: Methadone treatment for pain states. Am Fam Physician 2005;71:1353-1358.
32. Fainsinger RL, Nekolaichuk CL: A "TNM" classification system for cancer pain: The edmonton classification system for cancer pain (ECS-CP). Support Care Cancer 2008;16:547-555.
33. Ewing JA: Detecting alcoholism. The CAGE questionnaire. JAMA 1984;252:1905-1907.
34. Breitbart W, Rosenfeld B, Roth A, Smith MJ, Cohen K, Passik S: The memorial delirium assessment scale. J Pain Symptom Manage 1997;13:128-137.
35. Ferrell B, Levy MH, Paice J: Managing pain from advanced cancer in the palliative care setting. Clin J Oncol Nurs 2008;12:575-581.
36. Lawlor P, Walker P, Bruera E, Mitchell S: Severe opioid toxicity and somatization of psychosocial distress in a cancer patient with a background of chemical dependence. J Pain Symptom Manage 1997;13:356-361.
37. Walker G, Wilcock A, Carey AM, Manderson C, Weller R, Crosby V: Prolongation of the QT interval in palliative care patients. J Pain Symptom Manage 2003;26:855-859.
38. Golzari H, Dawson NV, Speroff T, Thomas C: Prolonged QTc intervals on admission electrocardiograms: Prevalence and correspondence with admission electrolyte abnormalities. Conn Med 2007;71:389-397.
39. Cruciani RA: Methadone: To ECG or not to ECG. . . that is still the question. J Pain Symptom Manage 2008;36:545-552.
40. Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MC: QTc interval screening in methadone treatment. Ann Intern Med 2009;150:387-395.
41. Medicines and Healthcare Products Regulatory Agency: Current Problems in Pharmacovigilance, Vol.31. London: Medicines and Healthcare Products Regulatory Agency, 2006.
42. Medicines and Healthcare Products Regulatory Agency: Methadone Maintenance Guidelines, Vol.20. Toronto, Ontario: Medicines and Healthcare Products Regulatory Agency, 2005.